Samrat Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE103E01016
  • NSEID:
  • BSEID: 530125
INR
258.95
6.65 (2.64%)
BSENSE

Dec 05

BSE+NSE Vol: 282

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Samrat Pharmachem Ltd stock-summary
stock-summary
Samrat Pharmachem Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Samrat Pharmachem Limited was incorporated on June 16, 1992. The Company's principal activities are manufacturing and selling chemicals. The Company floated a new 100% subsidiary company during the year 2003-04 named as Samrat Remedies Limited to carry on activities of Manufacturing of Pharmaceutical Bulk Drugs & Chemicals.
Company Coordinates stock-summary
Company Details
Plot No A2/3445, GIDC Phase IV Ankleshwar Gujarat : 393002
stock-summary
Tel: 91-2646-220774
stock-summary
samrat@bom4.vsnl.net.in
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR None Cr
Number of Shares
None Cr
Face Value
INR None
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 1 FIIs (3.24%)

Promoter with highest holding

Lalit Damodar Mehta (13.97%)

Highest Public shareholder

Sangeetha S (3.27%)

Individual Investors Holdings

41.73%

stock-summary Board of Directorsstock-summary
stock-summary
Management
Designation
Remuneration
Lalit Mehta
Chairman & Managing Director
36.0 lacs
Rajesh Mehta
Director & CFO
30.0 lacs
Mahendra Pipalia
Independent Director
2.0 lacs
Samir Kothary
Independent Director
2.0 lacs
Renu P Dharod
Independent Director
2.0 lacs
Megh Mehta
Executive Director
15.0 lacs
Nishant Kankaria
Company Sec. & Compli. Officer
2.43 lacs
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
Cost of Material Consumed
269.271
0%
 
100
Cost of Material Consumed
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Foreign Exchange Fluctuation
0.03
0.02%
 
0.02
Foreign Exchange Fluctuation
99.98
Foreign Exchange Fluctuation
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
79 Cr
(Quarterly Results - Sep 2025)
Net Profit:
-1 Cr
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 78 Cr (Micro Cap)

stock-summary
P/E

50.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.40%

stock-summary
Debt Equity

-0.12

stock-summary
Return on Equity

2.21%

stock-summary
Price to Book

1.10